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Abstract 
Children with refractory neurogenic bladder (NGB) who have failed maximal medical 
management are presented with options for bladder reconstruction. It is critical to understand 
the long-term sequela of bladder augmentation and bladder neck reconstruction to properly 
counsel families regarding these procedures. Benefits may include preservation of renal 
function, continence, reduced risk of renal-related mortality and potential improvements in 
quality of life (QOL). However, these advantages must be balanced with the risks of bladder 
calculi, perforation, need for additional surgery, acid/base disturbances, vitamin B12 deficiency 
and malignancy. Therefore, careful patient selection and preoperative counseling are 
paramount for those undergoing bladder reconstruction which includes intestinal bladder 
augmentation, as these patients require lifelong vigilant follow-up. 
 
Introduction 
Children with neurogenic bladders (NGB) are initially managed with clean intermittent 
catheterization (CIC) and anticholinergic medications in order to maintain a sizable, continent, 
and compliant urinary reservoir.  Despite early and aggressive intervention, some patients 
undergo lower urinary tract reconstruction (bladder augmentation, catheterizable channel and/or 
bladder neck reconstruction) to protect their upper tracts and achieve continence. In a few 
select patients with favorable urodynamics (UDS) and low outlet resistance, a bladder neck 
procedure (BNP) can be performed without bladder augmentation to achieve continence.  
Myelodysplasia, specifically spina bifida (SB), remains the most common etiology of NGB in the 
pediatric population. Due to medical advances, particularly in the realm of Urology, more SB 
patients with bladder reconstruction are surviving into adulthood. We review current literature 
regarding long-term sequela of bladder reconstruction in pediatric patients with neurogenic 
bladder, with a primary focus on bladder augmentations for refractory NGB secondary to SB. 
 
Bladder augmentation, the interposition of a piece of compliant tissue such as small bowel, 
large bowel, stomach, or ureter onto the native bladder, improves compliance by increasing 
bladder capacity and decreasing storage pressures.  Despite bladder augmentation serving as 
the gold standard for refractory NGB, most research has focused on its complications rather 
than its benefits. Improvement in continence, bladder capacity and upper tract preservation has 
been documented, however, scare published data exists regarding impact on QOL or overall 
renal function following bladder augmentation.  
 
Benefits 
The primary aim of bladder reconstruction is to improve both capacity and compliance. Poor 
bladder compliance leads to increased hydrostatic pressure during storage of urine which over 
time may lead to renal damage and renal failure, particularly with storage pressures > 40 
mmH2O (1). In addition, bladder augmentation, by reducing storage pressure, has been shown 
to improve urinary continence, decrease hydronephrosis and resolve low grade vesicoureteral 
reflux (VUR). 
 
Reduction in the Incidence of Renal Failure  
Following introduction of the ventricoperitoneal shunt (VPS), renal failure became the leading 
cause of mortality in the SB population, responsible for 25-30% of deaths beyond infancy (2). 
Renal function is typically normal at birth and deteriorates secondary to the abnormal physiology 
of NGB, however recent studies suggest that this deterioration is preventable. Szymanski et al. 
found renal failure as the cause of post-augmentation mortality in only 0.5% of SB patients who 
underwent bladder augmentation at 10 years (3). Compared to previously published rates, this 
data demonstrated a significant reduction in mortality due to renal failure in a cohort at high risk 
for developing renal failure. The authors’ conclusions are supported by a separate, modern era, 
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cohort of 120 SB patients, where no deaths were due to renal failure by age 20 (4). 
Furthermore, for patients managed with gastrocystoplasty due to poor renal function at the time 
of augmentation, most showed preserved or improved renal function (5). While studies appear 
to demonstrate that renal failure mortality is reduced in SB patients who have undergone 
bladder augmentation, there is no case-control data available revealing a renal failure mortality 
benefit of bladder augmentation. 
 
Continence/Bladder Capacity/Upper Tract Preservation 
Bladder augmentation improves urinary continence, bladder capacity, and preserves the upper 
tracts by reducing vesicoureteral reflux and hydroureteronephrosis secondary to poor 
compliance. (6-10). Krishna et al. found no evidence of progressive renal scarring or upper tract 
deterioration following bladder augmentation (10). Bladder augmentation with a concomitant 
bladder neck procedure results in a urinary continence rate ranging from 67-94% depending on 
the type of bladder neck reconstruction and length of follow-up (11-14). 
 
Urinary Tract Infections 
Diagnosing clinically significant urinary tract infections (UTIs) following bladder augmentation is 
often exceptionally difficult. Nearly all patients with augmented bladders must catheterize to 
empty, which results in bacterial colonization and asymptomatic bacteriuria. In addition, 
bacterial colonization of the augmented bowel segment is essentially universal and chronic. 
Thus, the diagnosis of UTI must incorporate a high index of clinical suspicion (fevers, new or 
worsening incontinence, foul odor, hematuria) in conjunction with a positive urine culture. In 
spite of this diagnostic dilemma, Krishna et al., have shown a reduction in the incidence and 
severity of UTIs following bladder augmentation (10).  
 
Quality of Life 
Bladder reconstruction has demonstrated positive effects on QOL including improved self-image 
and self-esteem (15). This impact has been questioned recently when MacNeily et al. failed to 
show any improvement in overall QOL following bladder augmentation in SB patients (16, 17). 
Importantly, the QOL instrument used by MacNeily et al. does not specifically ascertain the 
impact of fecal or urinary continence. These studies emphasize the need for utilization of 
specific, validated QOL instruments to accurately assess bowel and bladder function in this 
patient population. 
 
One such potential health-related QOL instrument has recently been developed and 
validated. QUAlity of Life Assessment in Spina Bifida in Adults (QUALAS-A) was created with 
participation of individuals with SB, their families and experts in SB care and has demonstrated 
excellent reliability and validity (18), Pediatric and teenage age-specific versions of QUALAS are 
undergoing validation at this time. As a SB-specific instrument, QUALAS may prove decidedly 
useful in clinical and research settings. 
 
Risks 
Although bladder reconstruction imparts multiple benefits, these are weighed against significant 
long-term risks, including calculi, acid/base disturbances due to absorption of urine by bowel, 
bladder perforation, B12 deficiency, and increased risk of malignancy. Despite advances in 
tissue engineering, variations in bowel substrates used to augment the bladder, and 
improvements in surgical techniques, the ideal tissue and technique for bladder reconstruction 
remain elusive (5, 19, 20). Furthermore, the ideal age to undertake bladder reconstruction also 
remains unclear, as patients 3-5 years old showed similar complications and reoperative risk 
compared to older patients (21). 
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Bladder reconstruction should be considered a permanent alteration to the lower urinary tract 
requiring close and lifelong observation. In the largest published series, complications were 
observed in 169 of 500 bladder augmentations (34%) resulting in an additional 254 surgeries, 
for a cumulative risk of further bladder-level surgery of 0.04 operations per patient per year 
following bladder reconstruction (22). However, two-thirds of patients with bladder 
augmentations did not require additional procedures during the time frame of the study. 
 
Bladder Calculi 
Bladder calculi often require operative intervention and are diagnosed in 11 – 52% of patients 
after bladder augmentation (22-26). Calculi typically form in bladders augmented with ileum 
and/or colon, when absorbable staples are used, in the setting of incomplete bladder emptying, 
and in patients with a metabolic predisposition for stone formation (hypocitraturia).  Bladder 
calculi are rare in gastric augments (5, 27-29). Other factors shown to increase risk of bladder 
calculi include: recurrent urinary tract infections, non-compliance with catheterizations or 
irrigations, and poor adherence to follow-up (30, 31). It is a common belief that bladder calculi 
share an infectious etiology; however, 30% have been found to be non-infectious (32). Several 
factors may contribute to stone formation, including chronic metabolic acidosis, resultant chronic 
kidney disease, and hypercalciuria related to wheel-chair dependence related osteodystrophy. 
Recent evidence by Kisku, et al. revealed exstrophy/epispadias and recurrent UTIs as 
independent risk factors for developing bladder calculi in patients with bladder augmentations 
(33). 
 
Studies revealed a median time to stone formation of 37.5 months (range 11-120 months) (33) 
and a high recurrence rate after treatment.  Indeed, between 15-29% of bladder calculi recur in 
less than 2 years (24). Depending on stone size and burden, multiple treatment modalities exist, 
ranging from endoscopic management to open cystolithotomy. Endoscopy for appropriately 
sized stones has demonstrated high rates of stone clearance with a low rate of complications 
(33) while preventing morbidity of entering the abdominal cavity. However, endoscopy via 
channel or urethra may result in injury to the channel or to a reconstructed bladder neck. It has 
been reported that surgical technique did not affect rate of bladder calculi recurrence (27, 28). 
This was recently confirmed by Szymanski, et al., who found that bladder stones recurred in 
almost half of patients within nine years following initial stone surgery independent of treatment 
modality or patient characteristics (36). 
 
The authors remove the majority of bladder stones through endoscopic, percutaneous or 
laparoscopic access, although approach is dependent on stone size, number, history of bladder 
neck procedure and presence of a catheterizable channel.  After stone removal, patients 
undergo a 24 urine collection and analysis, and evaluation in a multidisciplinary stone clinic to 
facilitate coordinated management with Urology and Nephrology (36). 
 
Metabolic Derangements 
Bowel segments continue their absorptive capacity despite being incorporated into the urinary 
tract, which may lead to metabolic derangements. Metabolic acidosis is relatively rare in 
patients with normal renal function who have undergone a bladder augmentation associated 
with use of a small bowel segment (37, 38). Hyperchloremic metabolic acidosis occurs with ileal 
and/or colonic segments secondary to the loss of bicarbonate and potassium. This process 
results from the reabsorption of ionized ammonium and chloride; ammonium is exchanged for a 
hydrogen proton, bicarbonate is exchanged for a chloride ion. Ionized ammonium can then be 
absorbed into the blood through potassium channels (39). Hypochloremic hypokalemic 
metabolic alkalosis can occur with the use of gastric segments (5) and hyponatremic 
hypochloremic hyperkalemic metabolic acidosis develops with the use of jejunum (40).  
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Chronic metabolic acidosis can lead to decreased bone mineral density and has raised concern 
for impaired linear growth following bladder augmentation in children; however, no studies have 
validated this theoretical complication (41). It remains feasible that prolonged acidosis may lead 
to osteomalacia or osteoporosis in adulthood (42). Metabolic acidosis should be corrected when 
diagnosed and patients provided calcium and vitamin D supplements. In some cases, 
bisphosphonates may become necessary to prevent loss of bone mass (41, 43-45). 
 
Perforation 
The utmost morbid and catastrophic complication following bladder augmentation is perforation, 
which may culminate in peritonitis, sepsis and even death. Reported rates of bladder perforation 
following augmentation range between 6-13% (9, 22, 46-49). Perforation occurs due to 
increased intravesical pressure, which may result from chronic bladder over-distention, chronic 
infection, traumatic catheterization, and ischemic necrosis of the intestinal segment used for the 
augmentation (50-56). Bladder perforation usually demands exploratory laparotomy with 
externalization of VPS (if present), to reduce the risk of CNS infections. In select patients 
without VPS, conservative management with catheter drainage, percutaneous drains, and close 
monitoring can be successful (57).  
 
In the largest published series, 43 out of the 500 patients (8.6%) who underwent bladder 
augmentation suffered a perforation. Increased risk of perforation was associated with the use 
of non-detubularized sigmoid colon, presence of a bladder neck procedure, and history of prior 
bladder perforation, while presence of a continent catheterizable channel was protective for 
perforation. Bladder perforation remains a lifelong risk following bladder augmentation, with one 
third occurring within 2 years, another third between 2 and 6 years, and the final third occurring 
after 6 years following initial surgery (22). 
 
Physicians must possess a high clinical suspicion for a perforated bladder augmentation due to 
impaired sensation in spina bifida patients. A detailed history, physical examination to assess 
for peritonitis, and laboratory analysis including white blood count and serum creatinine are 
useful when diagnosing bladder perforation. Patients with history of bladder augmentation who 
present with acute abdominal pain, poor urine output, elevated serum creatinine, and elevated 
white blood count should be urgently evaluated for possible bladder perforation. A low-pressure 
CT cystogram, including post-drainage film, remains the gold standard for diagnosing bladder 
perforation by evaluating for contrast extravasation into the peritoneal space (22, 55).  
 
Vitamin B12 Deficiency 
Hypocobalaminemia, or vitamin B12 deficiency, defined as a serum B12 concentration less than 
200 pg/mL, can occur after bladder augmentation with symptoms ranging from occult to 
dramatic. Patients with hypocobalaminemia may present with pernicious anemia, characterized 
by megaloblastic anemia, gastrointestinal symptoms, and potentially irreversible neurological 
symptoms including peripheral neuropathy, loss of positional and vibrational sense, ataxia, 
seizures, and dementia (58, 59). The risk of hypocobalaminemia is thought to increase 
approximately 5 years after augmentation and continues to escalate over time (60, 61).  
 
Vitamin B12 can be replaced parenterally or orally. Oral replacement is generally well-tolerated 
and effective in increasing serum B12 levels for the short term, however, long-term oral 
replacement success is poor, possibly due to reduced patient compliance (62, 63). Fortunately, 
hypocobalaminemia is often asymptomatic but the potentially devastating, irreversible 
neurologic complications make its diagnosis and treatment essential. A review of 23 patients 
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with augmented bladders with serum B12 levels <300 pg/mL revealed no evidence of pernicious 
anemia at a mean of 49 months following initial abnormal B12 level (63). 
 
Our practice advocates checking serum B12 annually in patients starting 5 years after bladder 
augmentation. Patients with serum B12 levels <100 pg/mL are initiated on parenteral 
replacement therapy and referred to neurology. Patients with serum B12 levels <300 pg/mL are 
started on oral replacement therapy with a daily multivitamin containing 250 mcg B12. Serum 
B12 levels are then reassessed every 3 months. If hypocobalaminemia persists, the patient is 
converted to parenteral therapy. Patients who respond well to oral replacement are monitored 
annually and converted to a parenteral replacement if hypocobalaminemia recurs. 
 
Malignancy 
Cancer in augmented bladders is an ever-present concern (64-72), confirmed by several large 
series reporting an incidence ranging from 1.1-4.5%. Soergel et al. reported urothelial 
carcinoma in 3/260 patients who underwent bladder augmentation for neurogenic bladder with 
at least 10 years follow up (69). Husmann and Rathbun found a 4.5% incidence of bladder 
cancer in 153 bladder augment patients with a minimum of 10-year follow-up. Higher rates of 
bladder cancer were associated with well-known carcinogenic stimuli, e.g., prolonged tobacco 
exposure, chronic immunosuppression, and bladder exstrophy (73). Patients with gastric 
augmentation appear to develop tumors more frequently and earlier after surgery compared to 
patients with ileal augmentation.  If this association is due to the interposition of a gastric 
segment, or because gastrocystoplasty was preferred in a high risk population, i.e., patients with 
renal failure and/or renal transplant, remains unclear (70, 72).  
 
Interestingly, patients with neurogenic bladder managed solely with clean intermittent 
catheterization have also demonstrated an increased risk of bladder cancer, and this risk may 
be increased following bladder augmentation (74). 
 
Some physicians recommend yearly endoscopy for potential early detection of malignant 
bladder tumors in the augment population (13, 75-77). However, others argue that yearly 
endoscopy is not cost effective and the potential morbidity makes it an ineffective screening 
procedure (78, 79). A decision analysis performed by Kokorowski et al. determined that annual 
screening cystoscopy and cytology were not cost-effective (80). Higuchi et al. have 
recommended cystoscopy in patients with four or more symptomatic UTIs per year, gross 
hematuria, microscopic hematuria with 50 or more RBC/hpf, abnormal radiographic screening 
studies, chronic perineal, pelvic or bladder pain, and for patients with colonic augments age 50 
or older (consistent with colonoscopy recommendations) (79, 81).  Any significant change in a 
patient’s baseline function may merit investigation with anatomic or functional studies for this 
vulnerable population at the clinical discretion of the Urologist.  
 
Catheterizable Channels 
Catheterizable channels are often created concomitantly to bladder augmentation procedures to 
facilitate ease of intermittent catheterization for patients with limited mobility and dexterity. 
Channels may be created from appendix (appendicovesicostomy, APV) or a segment of 
tubularized ileum (Monti ileovesicostomy), both of which have a low rate of stomal stenosis at 
<10%, and a high rate of continence at > 95%. While stomal stenosis, stomal revision 
procedures and channel continence were similar between APV and Monti channels, patients 
who underwent Monti catheterizable channels were twice as likely to require subfascial revision 
at 10 years follow-up. The longer spiral Mmonti channels to the umbilicus carried the greatest 
requirement for subfascial revision (82, 83). Complications continued to arise over the lifetime of 
the channel. Channel creation can increase a patient’s ability to discretely and independently 
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empty their bladder, however, just as with any bladder reconstruction, patients and families 
must be appropriately counseled of the long-term risks and benefits of this procedure. 
 
Bladder Neck Procedures 
Bladder neck reconstruction is often used to manage urinary incontinence; however, multiple 
types of bladder neck repairs have been utilized with variable success rates. Szymanski, et al. 
reported that the Kropp (n=38) and Salle (n=12) urethral lengthening procedures both displayed 
durable long-term outcomes with follow up of 6.9 and 10.3 years respectively. Kropp and Salle 
procedures attain 75-78% continence at greater than 4 hour intervals and 88-94% at greater 
than 3 hour intervals. The majority of patients with these types of bladder neck reconstructions 
did not require any additional procedures for continence (84).  
 
Although primarily used in the exstrophy-epispadias population, the Young-Dees-Leadbetter 
(YDL) repair also has reported adequate long-term continence rates. In a cohort of 38 patients, 
Donnahoo, et al. found that 30 patients were continent and 7 patients were partially continent. In 
this cohort, 26 patients required only one procedure, while 8 required 2 procedures and 3 
required more than 2 procedures to achieve continence (85). More recently, it has been shown 
that quality of life in female patients who have undergone a YDL repair is similar to a normal 
population (86). 
 
Bladder neck slings (BNS) and artificial urinary sphincters (AUS) are also feasible options for 
treatment of sphincteric dysfunction. After an average of 4.2 years, 51 of 58 patients had 
achieved continence after a rectus fascia BNS (87). Small intestinal submucosal bladder neck 
slings achieve satisfactory rates of continence (>75%) at a mean of 15 months follow up in 
14/18 females and 75% of non-ambulatory males who underwent concomitant bladder 
augmentation and catheterizable channel. Ambulatory males achieved a lower rate of 
continence (2/5, 40%) with bladder neck slings (88). Artificial urinary sphincters, unlike other 
bladder neck procedures, may still allow for spontaneous voiding in the neurogenic bladder 
population. In 134 patients with AUS, continence was achieved in 86% and continence 
improved in an additional 4%. Approximately 25% of this population spontaneously voided, 
while the remainder required clean intermittent catheterization to fully empty their bladder (89).  
 
Isolated Bladder Neck Procedures 
Due to the long-term sequela of bladder augmentation, some urologists perform isolated 
bladder neck procedures in appropriately selected patients with low bladder outlet resistance. 
Studies have suggested that isolated bladder neck procedures without augmentation are safe in 
carefully selected patients. 
 
Snodgrass et al. initially reported a series of 75 BNPs without augmentation and 4 years of 
follow up in which 23% of patients developed hydronephrosis and 25% developed 
vesicoureteral reflux. The authors reported all cases of hydronephrosis resolved with medical 
management, while persistent reflux was managed with ureteral injection or re-implantation 
(90). However, an update of this cohort reveals 54% required additional continence procedures 
with 18% requiring augmentation cystoplasty, 46% developing vesicoureteral 
reflux/hydronephrosis and 21% developing newly diagnosed or worsening renal scarring. Upper 
tract changes, incontinence and elevated bladder pressures improved in all patients following 
augmentation cystoplasty (91). 
 
In contradistinction, a series of 15 consecutive patients who underwent isolated bladder neck 
repair all eventually underwent salvage bladder augment (92).  Finally in another series of 29 
patients with a mean follow-up of 8 years who underwent isolated BNP, Whittam et al. reported 
8 
 
delayed augment in 45% of patients at an average of 34.4 months (3-117 months) (93). Clearly, 
these studies demonstrate the need for close, life-long follow-up if isolated bladder neck 
procedures are performed.  In select instances, such approaches appear to be safe and 
effective while avoiding the morbidity associated with a bladder augmentation in nearly half of 
patients.  
 
Current Long Term Management Strategy 
At our institution, all pediatric SB patients with bladder reconstruction are followed in our 
multidisciplinary SB clinic, with adult patients evaluated in the transitional urology clinic. Annual 
renal bladder ultrasound is used to monitor upper tracts, with urodynamics reserved for patients 
who develop hydronephrosis (new or worse) or new incontinence to ensure adequate capacity 
of the augmented bladder.  Annual laboratory studies include a complete blood count and basic 
metabolic panel, with the addition of serum B12 measures beginning five years post-operatively. 
We encourage patients to perform daily bladder irrigations with normal saline to help prevent 
formation of bladder calculi. Lastly, we review the patient’s catheterization schedule to identify 
and address any new or evolving difficulties. 
 
Conclusion 
Bladder reconstruction, including bladder augmentation, for refractory neurogenic bladder 
remains a mainstay of therapy for patients failing conservative management. Bladder 
reconstruction improves continence and protects upper tracts from deterioration due to a high-
pressure bladder, which can reduce renal failure and mortality. Such reconstructions can 
additionally may improve a patient’s quality of life.  
 
However, bladder reconstruction carries considerable lifelong risks. Thus, it should only be 
pursued in appropriately selected patients after considerable counseling. Risks of bladder 
calculi, metabolic derangements, perforation, hypocobalaminemia, and malignancy must be 
explained in detail to the patient and their family. While there are significant benefits to 
performing bladder reconstruction, the long-term sequela of the surgery mandate a lifelong 
commitment from the patient, family, and their urologist. 
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